CareDx Inc rose to a 52-week high of $53.71 in recent trading, capping a powerful quarter for the transplant diagnostics company. The stock traded at $53.54, just 0.97% below its peak, on September 15, 2026.
The rally followed second-quarter 2026 results that surpassed Wall Street expectations across the board. Adjusted earnings per share came in at $0.37, beating the consensus estimate of $0.23. Total revenue was $131.9 million, or approximately $132 million, eclipsing forecasts of $113.82 million and reflecting a 52% increase from the prior-year period. Testing revenue alone reached $99.9 million.
Following the beat, CareDx raised its full-year outlook, according to InvestingPro. The company, which holds a leading position in transplant diagnostics, reported a market capitalization of $2.74 billion.
Analysts maintained mixed but generally constructive views on the stock. Canaccord Genuity reiterated a buy rating with a $65 price target, while H.C. Wainwright assigned a neutral rating with a $46 target.
Valuation metrics painted a nuanced picture. A Piotroski score of 9 — considered perfect — signaled strong financial health, and a PEG ratio of 0.22 suggested attractive valuation relative to growth prospects. However, InvestingPro noted the stock appeared overvalued compared with its calculated fair value.
CareDx shares have surged 275.74% over the past year, making the latest reading near their highest level in twelve months.
